AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/25/21

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) , a mid-cap biotech company, closed trading Monday up by a healthy 26%. The stock raced higher in response to the FDA's approval of the company's oral lupus nephritis drug, Lupkynis (aka voclosporin). Lupkynis is indicated for pat...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Aurinia Pharmaceuticals Receives FDA Approval for LUPKYNIS” Aurinia Pharmaceuticals (NASDAQ: AUPH) soared over 37% in premarket trading after the FD...

Aurinia Pharmaceuticals (AUPH) has surged ~24.5% in response to its late Friday announcement of FDA approval for LUPKYNIS (voclosporin) for adults with active lupus nephritis.In a conference call arranged to discuss the regulatory win, the company estimated that the average ann...

Express (EXPR) +131%.TS Innovation Acquisitions (TSIA) +82% on merger agreement with Latch Inc..Aemetis (AMTX) +60%.Spartan Acquisition Corp. II (SPRQ) +51% on entering into business combination agreement with Sunlight.VYNE Therapeutics (VYNE) +40%.GameStop (GME) +43%.Aurinia Pharma...

The FDA has approved LUPKYNISTM (voclosporin) from Aurinia Pharmaceuticals Inc. (AUPH) as a treatment for adults with active lupus nephritis (“LN”) in combination with a background immunosuppressive therapy regimen.Aurinia rose ~14.1% during the five-day period leading...

- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissio...

AUPH stock has fallen on two recent developments. I analyze these and argue that the second, a new licensing agreement, is not negative, rather it's a positive for stockholders. I also review some of the secondary endpoint data which I believe will help accelerate the adoption of ...

Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks. Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug Voclosporin. Voclosporin approval by the FDA is almost assured thanks to the very good ph...